Brady James Aloysius — SEC Form 4 filings
SEC reporting owner CIK 1916987. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-05.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-04-30 to 2026-06-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 11,658 shares, $70,866 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 10,834 shares @ $5.54 ($60,036) in Xeris Biopharma Holdings, Inc., filed 2026-04-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | Director | 3 | — | 1 leg · 10,834 sh · $60,036 | 3 |
| Verona Pharma plc (VRNA) | Director | 4 | — | 1 leg · 824 sh · $10,830 | 11 |
Form 4 filings — Brady James Aloysius
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-04-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 10,834 @ $5.54 | EDGAR |
| 2025-10-08 | 4 | Verona Pharma plc (VRNA) | Disposition to issuer (D): 23,176 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 288,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +1 more | EDGAR |
| 2025-08-05 | 4 | Verona Pharma plc (VRNA) | Option exercise (M): 24,000 @ $0 · Sale (S): 824 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2024-04-30 | 4 | Verona Pharma plc (VRNA) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1916987 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →